Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC-Reference-Cited by-同舟云学术

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC

Published:2018-10 Issue:10 Volume:13 Page:1530-1538
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lin Jessica J.,Zhu Viola W.,Schoenfeld Adam J.,Yeap Beow Y.,Saxena Ashish,Ferris Lorin A.,Dagogo-Jack Ibiayi,Farago Anna F.,Taber Angela,Traynor Anne,Menon Smitha,Gainor Justin F.,Lennerz Jochen K.,Plodkowski Andrew J.,Digumarthy Subba R.,Ou Sai-Hong Ignatius,Shaw Alice T.,Riely Gregory J.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. New driver mutations in non–small-cell lung cancer;Pao;Lancet Oncol,2011

2. Identification of the transforming EML4-ALK fusion gene in non–small-cell lung cancer;Soda;Nature,2007

3. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

4. Targeting ALK: precision medicine takes on drug resistance;Lin;Cancer Discov,2017

5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs;Journal of Translational Medicine;2024-06-20

2. Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy;Journal of Nanoparticle Research;2024-05

3. Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC;Cancer Medicine;2024-04

4. Targeted therapeutic options in early and metastatic NSCLC-overview;Pathology and Oncology Research;2024-03-28

5. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study;Cancer Communications;2024-02-29